384 related articles for article (PubMed ID: 28063196)
41. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
[TBL] [Abstract][Full Text] [Related]
42. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia.
Kuchenbauer F; Feuring-Buske M; Buske C
Cell Cycle; 2005 Dec; 4(12):1716-8. PubMed ID: 16294039
[TBL] [Abstract][Full Text] [Related]
43. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
[TBL] [Abstract][Full Text] [Related]
44. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.
Cheng CK; Li L; Cheng SH; Ng K; Chan NP; Ip RK; Wong RS; Shing MM; Li CK; Ng MH
Blood; 2011 Dec; 118(25):6638-48. PubMed ID: 22031861
[TBL] [Abstract][Full Text] [Related]
45. POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.
Fortier JM; Payton JE; Cahan P; Ley TJ; Walter MJ; Graubert TA
Leukemia; 2010 May; 24(5):950-7. PubMed ID: 20376082
[TBL] [Abstract][Full Text] [Related]
46. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
47. Complex t(8;13;21)(q22;q14;q22)--a novel variant of t(8;21) in a patient with acute myeloid leukemia (AML-M2).
Udayakumar AM; Alkindi S; Pathare AV; Raeburn JA
Arch Med Res; 2008 Feb; 39(2):252-6. PubMed ID: 18164974
[TBL] [Abstract][Full Text] [Related]
48. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
Peterson LF; Boyapati A; Ahn EY; Biggs JR; Okumura AJ; Lo MC; Yan M; Zhang DE
Blood; 2007 Aug; 110(3):799-805. PubMed ID: 17412887
[TBL] [Abstract][Full Text] [Related]
49. Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia.
Flach J; Shumilov E; Joncourt R; Porret N; Tchinda J; Legros M; Scarpelli I; Hewer E; Novak U; Schoumans J; Bacher U; Pabst T
Genes Chromosomes Cancer; 2020 Apr; 59(4):268-274. PubMed ID: 31756777
[TBL] [Abstract][Full Text] [Related]
50. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
51. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
[TBL] [Abstract][Full Text] [Related]
52. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
[No Abstract] [Full Text] [Related]
53. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C
Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110
[TBL] [Abstract][Full Text] [Related]
54. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.
Al-Harbi S; Aljurf M; Mohty M; Almohareb F; Ahmed SOA
Blood Adv; 2020 Jan; 4(1):229-238. PubMed ID: 31935293
[TBL] [Abstract][Full Text] [Related]
55. Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.
Jahn N; Agrawal M; Bullinger L; Weber D; Corbacioglu A; Gaidzik VI; Schmalbrock L; Thol F; Heuser M; Krauter J; Göhring G; Kündgen A; Fiedler W; Wattad M; Held G; Köhne CH; Horst HA; Lübbert M; Ganser A; Schlenk RF; Döhner H; Döhner K; Paschka P
Leukemia; 2017 Apr; 31(4):1012-1015. PubMed ID: 28090090
[No Abstract] [Full Text] [Related]
56. Three way translocation in a new variant of t(8;21) acute myeloid leukemia involving Xp22.
Vundinti BR; Kerketta L; Madkaikar M; Jijina F; Ghosh K
Indian J Cancer; 2008; 45(1):30-2. PubMed ID: 18453738
[TBL] [Abstract][Full Text] [Related]
57. Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia.
Junge A; Zandi R; Havgaard JH; Gorodkin J; Cowland JB
Gene; 2017 Jun; 615():35-40. PubMed ID: 28322996
[TBL] [Abstract][Full Text] [Related]
58. MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death.
Ding C; Chen SN; Macleod RAF; Drexler HG; Nagel S; Wu DP; Sun AN; Dai HP
Ups J Med Sci; 2018 Mar; 123(1):19-27. PubMed ID: 29493383
[TBL] [Abstract][Full Text] [Related]
59. Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.
Steinauer N; Guo C; Huang C; Wong M; Tu Y; Freter CE; Zhang J
Blood Adv; 2019 May; 3(9):1379-1393. PubMed ID: 31040112
[TBL] [Abstract][Full Text] [Related]
60. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
